Biopharma AI
ByWill Big Pharma’s Billion-Dollar AI Investments Reshape the US$2 Trillion Pharmaceutical Industry Faster Than the Next Blockbuster Drug?
Key Highlights The AI Investment Race Has Officially Begun Artificial intelligence has rapidly evolved from an experimental technology…
Can Bristol Myers Squibb’s Enterprise-Wide Rollout of Anthropic’s Claude to 30,000 Employees Unlock Billions in AI-Driven Value and Redefine Biopharma’s Digital Future?
Key Highlights From AI Investment to Business Value Creation Bristol Myers Squibb’s enterprise-wide adoption of Anthropic’s Claude represents…
Can Edison Scientific and Population Health Partners’ AI Build the Next $10 Billion Biotech?
Key Highlights The Deal at a Glance Announced on June 29, 2026, the partnership pairs PHP’s proven track…
Can a $2.5 Billion AI Alliance Between Insilico Medicine and SK Biopharmaceuticals Rewrite the Future of Neuroimmune Drug Discovery?
Key Highlights The Deal at a Glance Announced at the BIO 2026 International Convention, the collaboration grants Insilico…
Can Attovia Therapeutics’ Nasdaq IPO Signal a Broader Biotech Funding Revival Backed by Goldman Sachs and Deep Track Capital?
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to file for a…
Can OpenLoop’s Acquisition of Hey Revia Redefine How AI Automates Telehealth Communication for Thousands of Providers?
Key Highlights A Landmark Acquisition Strengthening OpenLoop’s Virtual Care Ecosystem OpenLoop, the Iowa-based telehealth infrastructure company known for…
